NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
Clinical Trials
237 trialsNCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT05366842 2026-01-30
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
Johns Hopkins University
Phase 2 Terminated
NCT03553602 2026-01-29
BEACON
Loyola University
Phase 1/2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT02772562 2025-12-12
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Medical University of South Carolina
Phase 2 Terminated
NCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT04635059 2025-11-17
BLAST
Medical College of Wisconsin
Phase 2 Terminated
NCT05617040 2025-11-10
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Barinthus Biotherapeutics
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04616547 2025-10-03
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03432897 2025-07-08
337
Brown University
Phase 2 Terminated
NCT04740034 2025-06-17
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Amgen
Phase 1 Terminated
NCT03712371 2025-06-10
Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients
Medical University of South Carolina
Phase 1/2 Terminated
NCT01673984 2025-05-23
GREAT
Ipsen
Phase 4 Terminated
NCT04927663 2025-05-20
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
University of California, San Francisco
Phase 1 Terminated
NCT00635167 2025-05-16
Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
Thomas Jefferson University
Phase NA Terminated
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03300505 2025-05-13
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT05177770 2025-05-08
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Coherus Oncology, Inc.
Phase 2 Terminated
NCT04607135 2025-05-06
ARFI Imaging for Targeted Prostate Biopsy
Duke University
Phase NA Terminated
NCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04556617 2025-04-08
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Opna Bio LLC
Phase 1/2 Terminated
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT04382898 2025-03-20
PRO-MERIT
BioNTech SE
Phase 1/2 Terminated
NCT04298983 2025-03-19
RAD 1805
University of Alabama at Birmingham
Phase 2 Terminated
NCT04032704 2025-03-10
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 2 Terminated
NCT03152786 2025-02-17
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Wake Forest University Health Sciences
Phase 2 Terminated
NCT05501548 2025-01-29
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04134208 2025-01-16
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 4 Terminated
NCT05917470 2024-12-11
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
Oncternal Therapeutics, Inc
Phase 1/2 Terminated
NCT03777982 2024-09-19
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute
Phase 3 Terminated
NCT00773773 2024-09-04
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Terminated
NCT00321698 2024-08-29
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT03056638 2024-08-28
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Terminated
NCT04159896 2024-07-16
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03690141 2024-06-21
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Effector Therapeutics
Phase 2 Terminated
NCT03632655 2024-05-31
A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches
Weill Medical College of Cornell University
Phase NA Terminated
NCT01794936 2024-05-29
Pilot Study of VTI Doppler Probe Use to Identify Neurovascular Bundle During Prostate Surgery
Columbia University
Phase NA Terminated
NCT03458234 2024-05-20
RAD1801
University of Alabama at Birmingham
Phase NA Terminated
NCT01393119 2024-04-22
Phase II, Dose Finding Study of GTx-758
GTx
Phase 2 Terminated
NCT03810105 2024-04-09
A Study of Olaparib and Durvalumab in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT03657108 2024-03-20
CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation
Icahn School of Medicine at Mount Sinai
Phase NA Terminated
NCT03533946 2024-03-13
ROAR
University of Utah
Phase 2 Terminated
NCT04727736 2024-02-15
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
University of Pittsburgh
Phase 2 Terminated
NCT03577028 2024-02-14
Study of HPN424 in Patients With Advanced Prostate Cancer
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Terminated
NCT02995330 2024-02-13
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated